Clinical Trial Update: Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis. [Phase 2]

View source ↗

Summary

Phase 2 dose-ranging trial evaluating delgocitinib cream at 1, 3, 8, and 20 mg/g versus vehicle over 8 weeks in adults with atopic dermatitis; results posted af…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Delgocitinib Cream (delgocitinib)

Snippet

Sponsor: LEO Pharma | Conditions: Atopic Dermatitis | Phase 2 | Status: COMPLETED | Results posted: 2021-07-08